Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung

Proteomics

Volumn 15, Issue 18, 2015, Pages 3267-3277

  Rice, Shawn J ^a   Liu, Xin ^a   Miller, Bruce ^a   Joshi, Monika ^a   Zhu, Junjia ^a   Caruso, Carla ^a   Gilbert, Chris ^a   Toth, Jennifer ^a   Reed, Michael ^b   Rassaei, Negar ^a   Das, Arun ^a   Barochia, Amit ^a   El Bayoumy, Karam ^a   Belani, Chandra P ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Biomedicine; ITRAQ; Smoking; Squamous metaplasia

Indexed keywords

APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN C4; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13A; C REACTIVE PROTEIN; CD5 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT FACTOR H; FICOLIN 2; HEMOGLOBIN A2; IMMUNOGLOBULIN J CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LYCOZYME C; MANNAN BINDING LECTIN; PREALBUMIN; SERUM AMYLOID A; TALIN 1; THROMBOSPONDIN 1; TROPOMYOCIN ALPHA 3; TUMOR MARKER; UNCLASSIFIED DRUG; VITAMIN D BINDING PROTEIN; PLASMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG SQUAMOUS CELL METAPLASIA; MALE; MIDDLE AGED; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SMOKING; SQUAMOUS CELL METAPLASIA; WESTERN BLOTTING; YOUNG ADULT; BLOOD; ISOTOPE LABELING; LUNG; METAPLASIA; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; APOLIPOPROTEINS E; BIOMARKERS, TUMOR; BLOOD PROTEINS; FEMALE; HUMANS; ISOTOPE LABELING; LUNG; MALE; METAPLASIA; MIDDLE AGED; PROTEOMICS; ROC CURVE; SMOKING; YOUNG ADULT;

EID: 84941742232     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201500029     Document Type: Article

References (52)

1. Yabroff, K. R., Lamont, E. B., Mariotto, A., Warren, J. L. et al., Cost of care for elderly cancer patients in the United States. J. Natl. Cancer Inst. 2008, 100, 630-641.
2. Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29.
3. Howlader, N., Noone, A. M., Yu, M., Cronin, K. A., Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. Am. J. Epidemiol. 2012, 176, 347-356.
4. Humphrey, L. L., Deffebach, M., Pappas, M., Baumann, C. et al., Screening for lung cancer with low-dose computed tomography: a systematic review to update the US preventive services task force recommendation. Ann. Intern. Med. 2013, 159, 411-420.
5. Kathuria, H., Gesthalter, Y., Spira, A., Brody, J. S., Steiling, K., Updates and controversies in the rapidly evolving field of lung cancer screening, early detection, and chemoprevention. Cancers 2014, 6, 1157-1179.
6. Matt, P., Fu, Z., Fu, Q., Van Eyk, J. E., Biomarker discovery: proteome fractionation and separation in biological samples. Physiol. Genomics 2008, 33, 12-17.
7. Hartwell, L., Mankoff, D., Paulovich, A., Ramsey, S., Swisher, E., Cancer biomarkers: a systems approach. Nat. Biotechnol. 2006, 24, 905-908.
8. Gold, L., Ayers, D., Bertino, J., Bock, C. et al., Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 2010, 5, e15004.
9. Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F. et al., On the development of plasma protein biomarkers. J. Proteome Res. 2011, 10, 5-16.
10. Rifai, N., Gillette, M. A., Carr, S. A., Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 2006, 24, 971-983.
11. Izbicka, E., Streeper, R. T., Michalek, J. E., Louden, C. L. et al., Plasma biomarkers distinguish non-small cell lung cancer from asthma and differ in men and women. Cancer Genomics Proteomics 2012, 9, 27-35.
12. Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L. et al., Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 2008, 359, 366-377.
13. Fortunato, O., Boeri, M., Verri, C., Conte, D. et al., Assessment of circulating microRNAs in plasma of lung cancer patients. Molecules 2014, 19, 3038-3054.
14. Diamandis, E. P., Goodglick, L., Planque, C., Thornquist, M. D., Pentraxin-3 is a novel biomarker of lung carcinoma. Clin. Cancer Res. 2011, 17, 2395-2399.
15. Ajona, D., Pajares, M. J., Corrales, L., Perez-Gracia, J. L. et al., Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J. Natl. Cancer Inst. 2013, 105, 1385-1393.
16. Cho, J. Y., Sung, H. J., Proteomic approaches in lung cancer biomarker development. Expert. Rev. Proteomics 2009, 6, 27-42.
17. Nolen, B. M., Langmead, C. J., Choi, S., Lomakin, A. et al., Serum Biomarker profiles as diagnostic tools in lung cancer, Cancer Biomark, 2011, 10, 3-12.
18. Liu, L., Liu, J., Wang, Y., Dai, S. et al., A combined biomarker pattern improves the discrimination of lung cancer. Biomarkers 2011, 16, 20-30.
19. Bortner, J. D., Richie, J. P., Das, A., Liao, J. et al., Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. J. Proteome Res. 2011, 10, 1151-1159.
20. Tang, W. H., Shilov, I. V., Seymour, S. L., Nonlinear fitting method for determining local false discovery rates from decoy database searches. J. Proteome Res. 2008, 7, 3661-3667.
21. de Beer, J. C., Liebenberg, L., Does cancer risk increase with HbA1c, independent of diabetes? Br. J. Cancer 2014, 110, 2361-2368.
22. Grassadonia, A., Tinari, N., Natoli, C., Yahalom, G., Iacobelli, S., Circulating autoantibodies to LGALS3BP: a novel biomarker for cancer. Dis. Markers 2013, 35, 747-752.
23. Upur, H., Chen, Y., Kamilijiang, M., Deng, W. et al., Identification of plasma protein markers common to patients with malignant tumour and Abnormal Savda in Uighur medicine: a prospective clinical study. BMC Complement. Altern. Med. 2015, 15, 9.
24. Peng, G., Dan, W., Jun, W., Junjun, Y. et al., Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing. Tumour Biol. 2015, 36, 3309-3317.
25. Nie, S., Lo, A., Wu, J., Zhu, J. et al., Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J. Proteome Res. 2014, 13, 1873-1884.
26. Tang, H. Y., Beer, L. A., Tanyi, J. L., Zhang, R. et al., Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. J. Proteomics 2013, 89, 165-178.
27. Ding, H., Liu, J., Xue, R., Zhao, P. et al., Transthyretin as a potential biomarker for the differential diagnosis between lung cancer and lung infection. Biomed. Rep. 2014, 2, 765-769.
28. Liu, Z., Gao, Y., Hao, F., Lou, X. et al., Secretomes are a potential source of molecular targets for cancer therapies and indicate that APOE is a candidate biomarker for lung adenocarcinoma metastasis. Mol. Biol. Rep. 2014, 41, 7507-7523.
29. Shibutani, M., Maeda, K., Nagahara, H., Noda, E. et al., Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer. Surg. Today 2015, 45, 315-321.
30. Wang, Y., Chen, Z., Chen, J., Pan, J. et al., The diagnostic value of apolipoprotein E in malignant pleural effusion associated with non-small cell lung cancer. Clin. Chim. Acta 2013, 421, 230-235.
31. Su, W. P., Chen, Y. T., Lai, W. W., Lin, C. C. et al., Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer. Lung Cancer 2011, 71, 28-33.
32. Bouchal, P., Roumeliotis, T., Hrstka, R., Nenutil, R. et al., Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis. J. Proteome Res. 2009, 8, 362-373.
33. Tewari, A. K., Popova-Butler, A., El-Mahdy, M. A., Zweier, J. L., Identification of differentially expressed proteins in blood plasma of control and cigarette smoke-exposed mice by 2-D DIGE/MS. Proteomics 2011, 11, 2051-2062.
34. Ostroff, R. M., Bigbee, W. L., Franklin, W., Gold, L. et al., Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One 2010, 5, e15003.
35. Hakimi, A., Auluck, J., Jones, G. D., Ng, L. L., Jones, D. J., Assessment of reproducibility in depletion and enrichment workflows for plasma proteomics using label-free quantitative data-independent LC-MS. Proteomics 2014, 14, 4-13.
36. Pernemalm, M., Orre, L. M., Lengqvist, J., Wikström, P. et al., Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery. J. Proteome Res. 2008, 7, 2712-2722.
37. Xiao, D., Zhao, L. J., Chu, S. L., Jing, H., Wang, C., Proteomic analysis for detecting serum biomarkers related to smoking in humans. Chin. Med. J. 2012, 125, 3027-3032.
38. Bortner, J. D., Das, A., Umstead, T. M., Freeman, W. M. et al., Down-regulation of 14-3-3 isoforms and annexin A5 proteins in lung adenocarcinoma induced by the tobacco-specific nitrosamine NNK in the A/J mouse revealed by proteomic analysis. J. Proteome Res. 2009, 8, 4050-4061.
39. Linnoila, R. I., Szabo, E., DeMayo, F., Witschi, H. et al., The role of CC10 in pulmonary carcinogenesis: from a marker to tumor suppression. Ann. NY Acad. Sci. 2000, 923, 249-267.
40. Chen, J., Lam, S., Pilon, A., McWilliams, A. et al., The association between the anti-inflammatory protein CC10 and smoking status among participants in a chemoprevention trial. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 577-583.
41. Guo, X., Hao, Y., Kamilijiang, M., Hasimu, A. et al., Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis. Tumour Biol. 2015, 36, 1711-1720.
42. Zhang, G., Gomes-Giacoia, E., Dai, Y., Lawton, A. et al., Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature. Diagn. Pathol. 2014, 9, 200.
43. Rasmussen, K. L., Tybjaerg-Hansen, A., Nordestgaard, B. G., Frikke-Schmidt, R., Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann. Neurol. 2015, 77, 301-311.
44. Zhu, X., Ng, H. P., Lai, Y. C., Craigo, J. K. et al., Scavenger receptor function of mouse Fcγ receptor III contributes to progression of atherosclerosis in apolipoprotein E hyperlipidemic mice. J. Immunol. 2014, 193, 2483-2495.
45. Jamalzei, B., Fallah, S., Kashanian, M., Seifi, M., Association of the apolipoprotein E variants with susceptibility to pregnancy with preeclampsia. Clin. Lab. 2013, 59, 563-570.
46. Warita, K., Warita, T., Beckwitt, C. H., Schurdak, M. E. et al., Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci. Rep. 2014, 4, 7593.
47. Li, Z. G., Zhao, L., Liu, L., Ding, Y. Q., [Monitoring changes of serum protein markers in metastatic colorectal carcinoma model]. Zhonghua Bing Li Xue Za Zhi 2007, 36, 48-52.
48. Martin, P., Noonan, S., Mullen, M. P., Scaife, C. et al., Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. BMC Cancer 2014, 14, 887.
49. Breuer, R. H., Pasic, A., Smit, E. F., van Vliet, E. et al., The natural course of preneoplastic lesions in bronchial epithelium. Clin. Cancer Res. 2005, 11, 537-543.
50. Jeremy George, P., Banerjee, A. K., Read, C. A., O'Sullivan, C. et al., Surveillance for the detection of early lung cancer in patients with bronchial dysplasia. Thorax 2007, 62, 43-50.
51. Araya, J., Cambier, S., Markovics, J. A., Wolters, P. et al., Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients. J. Clin. Invest. 2007, 117, 3551-3562.
52. Ryan, D. M., Vincent, T. L., Salit, J., Walters, M. S. et al., Smoking dysregulates the human airway basal cell transcriptome at COPD risk locus 19q13.2. PLoS One 2014, 9, e88051.